No Data
Jiahe Biological-B (06998.HK): somerley cap has been appointed as the independent financial advisor.
On November 26, Glorious News announced that the board of directors of Jiahe Biological-B (06998.HK) is pleased to announce that Somerley Cap, a corporation licensed to conduct regulated activities under the Securities and Futures Ordinance for Type 1 (trade in securities) and Type 6 (advising on corporate finance), has been appointed as an independent financial advisor to provide advice on (i) the retention plan for Wong and the voting actions of the Listing Rules Independent Board Committee and independent shareholders; and (ii) the proposed merger, cleansing exemption, and shareholder personnel retention plan (including Wong's retention plan) as well as the voting actions before the Takeovers Code Independent Board Committee.
Jiahe Biology-B (06998) has appointed somerley cap as its independent financial advisor.
Jiahua Biotechnology-B (06998) announced that Somerley Cap Limited (a company licensed under the Securities and Futures Ordinance to...)
Due to restricted share units received, Genor Biopharma-B (06998) issued 0.125 million shares.
Jahwa Biological-B (06998) announced that on October 28, 2024, the company selected participants for...
Jiawei Bio - B [06998] is now trading at HKD 2.02, with a rise of 10.99%.
As of 13:47, KaHe Bio-B [06998] reported a price of 2.02 Hong Kong dollars, up 0.2 Hong Kong dollars or 10.99% from the closing price of 1.82 Hong Kong dollars yesterday. The turnover was 0.7659 million Hong Kong dollars. The highest price today is 2.02 Hong Kong dollars, and the lowest price is 1.8 Hong Kong dollars. Based on the closing price yesterday, the 10-day average price is 1.81 Hong Kong dollars, and the 50-day average price is 1.47 Hong Kong dollars. The current P/E ratio is -1.24 times, and the 14-day relative strength index is 60.00.
Yiteng Jia and "Transformation", the first shot of "value leap" was fired in the cold winter of biomedical capital.
With this integration, the new company's dual advantages in R&D and commercialization will make it more in line with the current market valuation trend for Biopharma companies, thereby possessing the potential for value reconstruction.
Jiahe Biotech-B (06998) has reached a major acquisition agreement with Yiteng Medicine, boosting the development of domestic innovative drugs.
On October 7th, Jiahao Biology-B (06998) announced a heavy acquisition with Yiteng Medicine, expecting to bring complementary and synergistic effects to both parties, and lay a good foundation for the sustainable development of the enlarged group after the merger is completed.
